Trade name | Active substance | Expenditure (EUR) | Share of total expenditure | Reimbursement category | |||||
---|---|---|---|---|---|---|---|---|---|
2010 | 2011 | 2012 | 2013 | 2014 | Total | ||||
Atriance | Nelarabine | 24 773 | 24 773 | 0.20 % | Individual reimbursement | ||||
Nexavar | Sorafenib | 16 418 | 12 040 | 23 806 | 17 786 | 14 229 | 84 278 | 0.68 % | |
Revatio | Sildenafil | 104 742 | 147 370 | 219 252 | 340 536 | 480 685 | 1 292 585 | 10.37 % | |
Volibris | Ambrisentan | 52 172 | 87 744 | 142 289 | 128 058 | 163 633 | 573 897 | 4.60 % | |
Exjade | Deferasirox | 5 726 | 7 329 | 13 055 | 0.10 % | ||||
Sprycel | Dasatinib | 60 450 | 60 450 | 0.48 % | |||||
Wilzin | Zinc | 1 317 | 169 | 1 486 | 0.01 % | ||||
Cystadane | Betaine | 1 038 | 3 142 | 2 094 | 4 327 | 6 560 | 17 161 | 0.14 % | |
Diacomit | Stiripentol | 6 696 | 8 940 | 14 354 | 11 424 | 16 947 | 58 360 | 0.47 % | |
Glivec | Imatinib | 47 731 | 68 608 | 116 340 | 0.93 % | ||||
Arzerra | Ofatumumab | 27 830 | 27 830 | 0.22 % | |||||
Mozobil | Plerixafor | 12 796 | 25 592 | 38 389 | 0.31 % | ||||
Nplate | Romiplostim | 13 687 | 13 687 | 0.11 % | |||||
Revolade | Eltrombopag | 3 790 | 3 790 | 0.03 % | |||||
Tracleer | Bosentan | 12 697 | 12 697 | 0.10 % | |||||
Glivec | Imatinib | 1 373 374 | 1 481 110 | 1 252 280 | 4 106 764 | 32.94 % | List A (previously List C) | ||
Sprycel | Dasatinib | 202 997 | 296 703 | 412 538 | 524 119 | 1 436 357 | 11.52 % | List C | |
Tasigna | Nilotinib | 149 561 | 275 615 | 285 964 | 711 140 | 5.70 % | |||
Wilzin | Zinc | 1 534 | 1 534 | 0.01 % | List B | ||||
Elaprase | Idursulfase | 418 275 | 501 228 | 596 232 | 681 408 | 707 619 | 2 904 762 | 23.30 % | CCUH program |
Kuvan | Sapropterin | 173 374 | 173 374 | 213 828 | 560 575 | 4.50 % | |||
Cystadane | Betaine | 6 265 | 6 265 | 6 416 | 18 945 | 0.15 % | |||
Increlex | Mecasermin | 94 257 | 93 557 | 93 820 | 281 634 | 2.26 % | |||
Myozyme | Alglucosidase alpha | 71 548 | 71 548 | 0.57 % | |||||
Votubia | Everolimus | 34 802 | 34 802 | 0.28 % | |||||
All Orphan Drugs | 2 064 981 | 2 550 574 | 3 064 669 | 2 144 887 | 2 641 727 | 12 466 838 | |||
Total Pharmaceutical Market | 276 690 000 | 290 190 000 | 295 480 000 | 307 590 000 | 316 040 000 | Average | |||
Share of Total Pharmaceutical Market | 0.75 % | 0.88 % | 1.04 % | 0.70 % | 0.84 % | 0.84 % | |||
Total Drug Reimbursement Budget | 105 911 722 | 118 204 402 | 117 007 689 | 117 384 880 | 122 326 421 | Average | |||
Share of Total Drug Reimbursement | 1.95 % | 2.16 % | 2.62 % | 1.83 % | 2.16 % | 2.14 % |